Author: admin

Follicular Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “Follicular Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Follicular Lymphoma Pipeline Report

  • DelveInsight’s Follicular Lymphoma Pipeline analysis depicts a robust space with 50+ Follicular Lymphoma companies working to develop 50+ pipeline treatment therapies.
  • The leading companies working in the Follicular Lymphoma Market include Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others.
  • Promising Follicular Lymphoma Pipeline Therapies in the various stages of development include DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.
  • December 2023: AbbVie announced a study of Phase 2 clinical trials for Epcoritamab, Rituximab and Lenalidomide. A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1).
  • On August 2023, AbbVie announced a study of phase 3 clinical trials for Epcoritamab, Rituximab, and Lenalidomide. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
  • On August 2023, Celgene announced a study of phase 3 clinical trias for Rituximab and Lenalidomide. The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.

 

Request a sample and discover the recent advances in Follicular Lymphoma Treatment Drugs @ Follicular Lymphoma Pipeline Outlook Report

 

In the Follicular Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Follicular Lymphoma Overview

Follicular lymphoma is a form of cancer. It is a type of non-Hodgkin lymphoma (NHL), which is a group of related cancers that affect the lymphatic system (lymphomas). The lymphatic system functions as part of the immune system and helps to protect the body against infection and disease. It consists of a network of tubular channels (lymph vessels) that drain a thin watery fluid known as lymph from different areas of the body into the bloodstream.

 

Find out more about Follicular Lymphoma Therapeutics Assessment @ Follicular Lymphoma Preclinical and Discovery Stage Products

 

Follicular Lymphoma Emerging Drugs Profile

  • Tafasitamab: Incyte Corporation
  • Epcoritamab: Genmab A/S
  • Zanubrutinib – BeiGene
  • Pembrolizumab: Merck & Co.

 

Follicular Lymphoma Pipeline Therapeutics Assessment

There are approx. 50+ Follicular Lymphoma companies which are developing the Follicular Lymphoma therapies. The Follicular Lymphoma companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III.

 

DelveInsight’s Follicular Lymphoma pipeline report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Follicular Lymphoma Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Follicular Lymphoma Pipeline Therapies @ Follicular Lymphoma Clinical Trials Assessment

 

Scope of the Follicular Lymphoma Pipeline Report

  • Coverage- Global
  • Follicular Lymphoma Companies- Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others.
  • Follicular Lymphoma Therapies- DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for new drugs for Follicular Lymphoma Treatment, Visit @ Follicular Lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Follicular Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Follicular Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Zanubrutinib – BeiGene
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Pembrolizumab: Merck & Co.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Follicular Lymphoma Key Companies
  21. Follicular Lymphoma Key Products
  22. Follicular Lymphoma- Unmet Needs
  23. Follicular Lymphoma- Market Drivers and Barriers
  24. Follicular Lymphoma- Future Perspectives and Conclusion
  25. Follicular Lymphoma Analyst Views
  26. Follicular Lymphoma Key Companies
  27. Appendix

 

For further information on the Follicular Lymphoma Pipeline therapeutics, reach out to Follicular Lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

Triple Negative Breast Cancer (TNBC) Market Insights 2032 Covering Epidemiology, Pipeline Therapies, and Recent Approvals from FDA, EMA, PDMA by DelveInsight | Featuring HiberCell, Roche, CytoDyn

“Triple Negative Breast Cancer (TNBC) Market”

DelveInsight’s “Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Triple Negative Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Triple Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Triple Negative Breast Cancer Market Forecast

 

Some of the key facts of the Triple Negative Breast Cancer Market Report: 

  • The Triple Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In June 2023, Gilead Sciences awarded the first “Towards Health Equity for Black People Impacted by Triple Negative Breast Cancer Resource Hub” grant to TOUCH, The Black Breast Cancer Alliance, the Triple Negative Breast Cancer Foundation, the American Association for Cancer Research (AACR), and Nueva Vida for their project Black TNBC Matters.
  • In May 2023, The National Medical Products Administration has approved the supplemental new drug application (“sNDA”) for Shanghai Junshi Biosciences Co., Ltd.’s anti-PD-1 monoclonal antibody, toripalimab, which is used in conjunction with albumin-bound paclitaxel to treat PD-L1 p.
  • In November 2022, The MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic TNBC patients was updated by Infinity Pharmaceutical
  • Between 2012 and 2016, 12% of breast cancer diagnoses in the United States were triple-negative, with a 5-year survival rate that was 8% to 16% poorer than that of hormone receptor-positive illness
  • In the year 2022, Germany had the most newly diagnosed incident instances of TNBC among the EU4 countries, accounting for almost 12,000 cases. France and Italy came in second and third, respectively
  • In the US, approximately 10,000 instances of triple-negative breast cancer were in the advanced stage in 2022
  • In 2022, Germany and Italy among the EU4 countries had the highest rates of TNBC cases in the advanced stages
  • Future treatments like Hoffman-La Roche’s TECENTRIQ, Infinity Pharmaceuticals’ Eganelisib, GX-I7 + KEYTRUDA, and others might significantly increase the size of the TNBC market from 2019 through 2032
  • Key Triple Negative Breast Cancer Companies: HiberCell, Hoffmann-La Roche, Infinity Pharma, CytoDyn, Valo Therapeutics, Medicenna, Jiangsu HengRui Medicine, G1 Therapeutics, BioLite Inc, Sanofi, X4 Pharmaceuticals, Phoenix Molecular Designs, and others
  • Key Triple Negative Breast Cancer Therapies: Imprime PGG, Tecentriq, IPI-549 (Eganelisib), Leronlimab (PRO 140), PeptiCRAd-1, MDNA11, Camrelizumab, Trilaciclib, Odetiglucan, BLEX 404, Mavorixafor, PMD-026, and others
  • The Triple Negative Breast Cancer epidemiology based on gender analyzed that Through various secondary domains it can be concluded that Triple Negative Breast Cancer affects females
  • The Triple Negative Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Triple Negative Breast Cancer pipeline products will significantly revolutionize the Triple Negative Breast Cancer market dynamics.

 

Triple Negative Breast Cancer Overview

The term “triple negative breast cancer” (TNBC) refers to a tumour in which the hormones oestrogen and progesterone (ER/PR) are negative as determined by immunohistochemistry (IHC), and neither HER2 overexpression nor its gene amplification as determined by fluorescence in situ hybridization technique.

 

Get a Free sample for the Triple Negative Breast Cancer Market Report 

https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market

 

Triple Negative Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Triple Negative Breast Cancer Epidemiology Segmentation:

The Triple Negative Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Triple Negative Breast Cancer
  • Prevalent Cases of Triple Negative Breast Cancer by severity
  • Gender-specific Prevalence of Triple Negative Breast Cancer
  • Diagnosed Cases of Episodic and Chronic Triple Negative Breast Cancer

 

Download the report to understand which factors are driving Triple Negative Breast Cancer epidemiology trends @ Triple Negative Breast Cancer Epidemiology Forecast

 

Triple Negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Triple Negative Breast Cancer market or expected to get launched during the study period. The analysis covers Triple Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Triple Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Triple Negative Breast Cancer Therapies and Key Companies

  • Imprime PGG: HiberCell
  • Tecentriq: Hoffmann-La Roche
  • IPI-549 (Eganelisib): Infinity Pharma
  • Leronlimab (PRO 140): CytoDyn
  • PeptiCRAd-1: Valo Therapeutics
  • MDNA11: Medicenna
  • Camrelizumab: Jiangsu HengRui Medicine
  • Trilaciclib: G1 Therapeutics
  • Odetiglucan: HiberCell
  • BLEX 404: BioLite Inc
  • Mavorixafor: Sanofi/X4 Pharmaceuticals
  • PMD-026: Phoenix Molecular Designs

 

Discover more about therapies set to grab major Triple Negative Breast Cancer market share @ Triple Negative Breast Cancer Treatment Market

 

Triple Negative Breast Cancer Market Strengths

  • Rise in TNBC market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radiotherapy techniques and novel systemic therapies.
  • Improvement in genomics and proteomics can lead to an acceleration in the discovery of novel treatment and drug deliverance.

 

Triple Negative Breast Cancer Market Opportunities

  • Increasing incidence trend will provide better therapeutic approaches for the TNBC market in the near future.
  • The market of TNBC lacks an effective strategy to cure the condition, which provides a lucrative opportunity to develop more treatment options.
  • Due to lack of competitors, there is a substantial market opportunity for key players to develop anaplastic tumour targeting therapies

 

Scope of the Triple Negative Breast Cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Triple Negative Breast Cancer Companies: HiberCell, Hoffmann-La Roche, Infinity Pharma, CytoDyn, Valo Therapeutics, Medicenna, Jiangsu HengRui Medicine, G1 Therapeutics, BioLite Inc, Sanofi, X4 Pharmaceuticals, Phoenix Molecular Designs, and others
  • Key Triple Negative Breast Cancer Therapies: Imprime PGG, Tecentriq, IPI-549 (Eganelisib), Leronlimab (PRO 140), PeptiCRAd-1, MDNA11, Camrelizumab, Trilaciclib, Odetiglucan, BLEX 404, Mavorixafor, PMD-026, and others
  • Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
  • Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Triple Negative Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Triple Negative Breast Cancer Market Access and Reimbursement 

 

To know more about Triple Negative Breast Cancer companies working in the treatment market, visit @ Triple Negative Breast Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Triple Negative Breast Cancer Market Report Introduction

2. Executive Summary for Triple Negative Breast Cancer

3. SWOT analysis of Triple Negative Breast Cancer

4. Triple Negative Breast Cancer Patient Share (%) Overview at a Glance

5. Triple Negative Breast Cancer Market Overview at a Glance

6. Triple Negative Breast Cancer Disease Background and Overview

7. Triple Negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Triple Negative Breast Cancer 

9. Triple Negative Breast Cancer Current Treatment and Medical Practices

10. Triple Negative Breast Cancer Unmet Needs

11. Triple Negative Breast Cancer Emerging Therapies

12. Triple Negative Breast Cancer Market Outlook

13. Country-Wise Triple Negative Breast Cancer Market Analysis (2019–2032)

14. Triple Negative Breast Cancer Market Access and Reimbursement of Therapies

15. Triple Negative Breast Cancer Market Drivers

16. Triple Negative Breast Cancer Market Barriers

17.  Triple Negative Breast Cancer Appendix

18. Triple Negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer (TNBC) Market Insights 2032 Covering Epidemiology, Pipeline Therapies, and Recent Approvals from FDA, EMA, PDMA by DelveInsight | Featuring HiberCell, Roche, CytoDyn

NASH Pipeline Review 2023: Analysis of New Therapies, Recent Approvals by FDA, EMA, and PMDA, Clinical Trials, and Treatment Prospects by DelveInsight

“NASH Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Alcoholic Steatohepatitis pipeline constitutes key companies continuously working towards developing Non-Alcoholic Steatohepatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Non-Alcoholic Steatohepatitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Steatohepatitis Market.

 

Some of the key takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Non-Alcoholic Steatohepatitis treatment therapies with a considerable amount of success over the years. 
  • Non-Alcoholic Steatohepatitis companies working in the treatment market are Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others, are developing therapies for the Non-Alcoholic Steatohepatitis treatment 
  • Emerging Non-Alcoholic Steatohepatitis therapies such as – GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others are expected to have a significant impact on the Non-Alcoholic Steatohepatitis market in the coming years.   
  • In January 2023, Resmetirom, a liver-directed selective thyroid hormone receptor agonist, was tested in the major Phase III MAESTRO-NASH biopsyclinical trial by Madrigal Pharmaceuticals, Inc. At the NASH-TAG Conference, the new MAESTRO-NASH results are being presented
  • In July 2022, To assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of orally administered TERN-501 as monotherapy as well as in combination with TERN-101 in Noncirrhotic Adults with Presumed Non-Alcoholic Steatohepatitis (NASH), TERN Therapeutics started a Phase IIa multicenter, randomised, double-blind, placebocontrolled clinical study
  • In August 2022 An international, multi-center, double-blind, randomised, placebo-controlled study was started by Madrigal Pharmaceuticals with patients who had well-compensated NASH cirrhosis. For the duration of the study and until the required number of Composite Clinical Outcome events are reached, participants will be blindly randomised 3:1 to receive either 80 mg of resmetirom or a matching placebo administered orally once daily in the morning
  • In November 2022, TERN-501, a thyroid hormone receptor beta (THR-) agonist being developed for the treatment of NASH, was the subject of a Phase 1 research, according to a statement from Terns Pharmaceuticals, Inc. At The Liver Meeting®, the annual conference of the American Association for the Study of Liver Diseases (AASLD), the findings are being emphasised in a poster session
  • In January 2021, The company’s IND for TERN-501, a selective thyroid hormone receptor beta, or THR-, agonist with improved metabolic stability and liver distribution, was approved by the US Food and Drug Administration. These features are meant to increase safety and efficacy in NASH patients
  • In October 2019, The US FDA has approved Madrigal Pharmaceuticals’ request for Fast Track designation for the use of resmetirom to treat NASH

 

Get a Free Sample PDF Report to know more about Non-Alcoholic Steatohepatitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Emerging Non-Alcoholic Steatohepatitis Drugs Under Different Phases of Clinical Development Include:

  • GMA-107: Gmax Biopharm
  • LBS-009: Lin Biosciences
  • VK-1430: Viking Therapeutics
  • Resmetirom: Madrigal Pharmaceuticals
  • MSDC-0602K: Cirius Therapeutics
  • ION224: Ionis Pharmaceuticals
  • HU 6: Rivus Pharmaceuticals
  • HTD 1801: HighTide Biopharma
  • EDP-305: Enanta Pharmaceuticals
  • SRT-015: Seal Rock Therapeutics
  • AZD 2693: AstraZeneca
  • BI 456906: Boehringer Ingelheim
  • ORMD-0801: Oramed Pharmaceuticals
  • EYP001: ENYO Pharma
  • TERN-501: Terns Pharmaceuticals
  • Semaglutide: NovoNordisk
  • Resmetirom: Madrigal Pharmaceuticals
  • Lanifibranor: Inventiva Pharma

 

Route of Administration

Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Non-Alcoholic Steatohepatitis Pipeline Therapeutics Assessment

  • Non-Alcoholic Steatohepatitis Assessment by Product Type
  • Non-Alcoholic Steatohepatitis By Stage and Product Type
  • Non-Alcoholic Steatohepatitis Assessment by Route of Administration
  • Non-Alcoholic Steatohepatitis By Stage and Route of Administration
  • Non-Alcoholic Steatohepatitis Assessment by Molecule Type
  • Non-Alcoholic Steatohepatitis by Stage and Molecule Type

 

DelveInsight’s Non-Alcoholic Steatohepatitis Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Non-Alcoholic Steatohepatitis product details are provided in the report. Download the Non-Alcoholic Steatohepatitis pipeline report to learn more about the emerging Non-Alcoholic Steatohepatitis therapies

 

Some of the key companies in the Non-Alcoholic Steatohepatitis Therapeutics Market include:

Key companies developing therapies for Non-Alcoholic Steatohepatitis are – Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, AstraZeneca, Inventiva Pharma, Cirius Therapeutics, Inc, Galectin Therapeutics Inc., Galmed Research and Development, Ltd., Zydus Therapeutics Inc., Rivus Pharmaceuticals, Inc., 89bio, Inc., Lipocine Inc., HighTide Biopharma Pty Ltd, Akero Therapeutics, Inc, Enyo Pharma, Sagimet Biosciences Inc., CytoDyn, Inc., Terns, Inc., Poxel SA, Enanta Pharmaceuticals, Inc, Kowa Company, Ltd., NorthSea Therapeutics B.V., Merck, NGM Biopharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, Gilead Sciences, Cascade Pharmaceuticals, Inc, Hepion Pharmaceuticals, Inc., Pfizer, Alnylam Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Future Medicine, Boston Pharmaceuticals, MediciNova, Cellaion, Promethera Therapeutics, Viking Therapeutics, Inc., Novo Nordisk A/S, Eccogene, CohBar, Inc., Aligos Therapeutics, Corcept Therapeutics, Altimmune, Inc., Janssen Pharmaceutical K.K., Enanta Pharmaceuticals, Inc, Arrowhead Pharma, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Novo Nordisk A/S, Metacrine, Inc., Hepagene (Shanghai) Co., Ltd., TaiwanJ Pharmaceuticals Co., Ltd, Viking Therapeutics, Inc., LG Chem, Redx Pharma, and others.

 

Non-Alcoholic Steatohepatitis Pipeline Analysis:

The Non-Alcoholic Steatohepatitis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Steatohepatitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Steatohepatitis Treatment.
  • Non-Alcoholic Steatohepatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non-Alcoholic Steatohepatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Steatohepatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Non-Alcoholic Steatohepatitis drugs and therapies

 

Non-Alcoholic Steatohepatitis Pipeline Market Drivers

  • Rise in prevalence, emerging treatment therapies of NASH, growing demand for NASH therapeutics are some of the important factors that are fueling the Non-Alcoholic Steatohepatitis Market.

 

Non-Alcoholic Steatohepatitis Pipeline Market Barriers

  • However, lack of analogs, use of combination therapies, reimbursement issues and other factors are creating obstacles in the Non-Alcoholic Steatohepatitis Market growth.

 

Scope of Non-Alcoholic Steatohepatitis Pipeline Drug Insight    

  • Coverage: Global
  • Key Non-Alcoholic Steatohepatitis Companies: Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others
  • Key Non-Alcoholic Steatohepatitis Therapies: GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others
  • Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies
  • Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers 

 

Request for Sample PDF Report for Non-Alcoholic Steatohepatitis Pipeline Assessment and clinical trials

 

Table of Contents

1

Non-Alcoholic Steatohepatitis Report Introduction

2

Non-Alcoholic Steatohepatitis Executive Summary

3

Non-Alcoholic Steatohepatitis Overview

4

Non-Alcoholic Steatohepatitis- Analytical Perspective In-depth Commercial Assessment

5

Non-Alcoholic Steatohepatitis Pipeline Therapeutics

6

Non-Alcoholic Steatohepatitis Late Stage Products (Phase II/III)

7

Non-Alcoholic Steatohepatitis Mid Stage Products (Phase II)

8

Non-Alcoholic Steatohepatitis Early Stage Products (Phase I)

9

Non-Alcoholic Steatohepatitis Preclinical Stage Products

10

Non-Alcoholic Steatohepatitis Therapeutics Assessment

11

Non-Alcoholic Steatohepatitis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Non-Alcoholic Steatohepatitis Key Companies

14

Non-Alcoholic Steatohepatitis Key Products

15

Non-Alcoholic Steatohepatitis Unmet Needs

16 

Non-Alcoholic Steatohepatitis Market Drivers and Barriers

17

Non-Alcoholic Steatohepatitis Future Perspectives and Conclusion

18

Non-Alcoholic Steatohepatitis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NASH Pipeline Review 2023: Analysis of New Therapies, Recent Approvals by FDA, EMA, and PMDA, Clinical Trials, and Treatment Prospects by DelveInsight

Insights into Ulcerative Colitis Market 2032: Epidemiological Trends, Pipeline Therapies, and Recent Approvals from FDA, EMA, PDMA Revealed by DelveInsight | Key Players: AbbVie, Boehringer, Eli Lilly

“Ulcerative Colitis Market”

(Albany, USA) DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerative Colitis Market Forecast

 

Some of the key facts of the Ulcerative Colitis Market Report: 

  • The Ulcerative Colitis market size was approximately USD 6,900 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • A Totoal of 2,223,000 people with Ulcerative Colitis were prevalent overall in the 7MM in 2022. During the prediction period (from 2023 to 2032), these cases are anticipated to increase
  • In the year 2022, the United States recorded the greatest prevalence of Ulcerative Colitis cases in the 7MM, with 1,026,000 cases, or roughly 46% of all cases
  • The country with the most cases of UC among the EU4 and the UK had 357,000 cases in 2022
  • The age range 18–44 years had the highest percentage of diagnosed Ulcerative Colitis cases (7MM), followed by 45–64 years (28%) and then 65–84 years (11%) and 85 years (1%), in 2022
  • In 2022, there were 740,000 diagnosed prevalent cases and 1,024,000 prevalent cases of UC combined in EU4 and the UK
  • Key Ulcerative Colitis Companies: AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mesoblast Ltd., InDex Pharmaceuticals, Arena, Protagonist Therapeutics, Palatin Technologies, Inc, Eli Lilly and Company, Pfizer, Janssen Research, Amgen, AbbVie, Landos Biopharma, Ferring Pharma, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma, EA Pharma, Prometheus Biosciences, and others
  • Key Ulcerative Colitis Therapies: isankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Remestemcel-L, Corbitolimod, Etrasimod (APD334), PN-943, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, PRA023 IV, and others
  • The Ulcerative Colitis epidemiology based on gender analyzed that moderate-to-severe UC cases accounts for ~55% of the total cases and the rest of the cases falls under mild category
  • The Ulcerative Colitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ulcerative Colitis pipeline products will significantly revolutionize the Ulcerative Colitis market dynamics.

 

Ulcerative Colitis Overview

Inflammation and ulcers on the inner lining of your large intestine are symptoms of the chronic inflammatory bowel disease (IBD) known as ulcerative colitis. Although ulcerative colitis can occur at any age, those between the ages of 15 and 30 have the highest risk of developing the condition.

 

Get a Free sample for the Ulcerative Colitis Market Report 

https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market

 

Ulcerative Colitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Ulcerative Colitis Epidemiology Segmentation:

The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Ulcerative Colitis
  • Prevalent Cases of Ulcerative Colitis by severity
  • Gender-specific Prevalence of Ulcerative Colitis
  • Diagnosed Cases of Episodic and Chronic Ulcerative Colitis

 

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ Ulcerative Colitis Epidemiology Forecast

 

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched during the study period. The analysis covers Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ulcerative Colitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Ulcerative Colitis Therapies and Key Companies

  • Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
  • Mirikizumab (LY3074828): Eli Lilly and Company
  • Tremfya (Guselkumab): Janssen
  • Remestemcel-L: Mesoblast Ltd.
  • Corbitolimod: InDex Pharmaceuticals
  • Etrasimod (APD334): Arena
  • PN-943: Protagonist Therapeutics

 

Discover more about therapies set to grab major Ulcerative Colitis market share @ Ulcerative Colitis Treatment Market

 

Ulcerative Colitis Market Strengths

  • With the market dynamics shifting towards medications with oral ROA, emergence of therapies like, BT-11,AJM300, Etrasimod, and SHR0302 will further drive the UC therapeutic market.
  • Robust emerging pipeline with novel MOAs with less immunogenicity such as cobitolimod, BBT-401,Omilancor, and others are likely to strengthen the market.

 

Ulcerative Colitis Market Opportunities

  • There lies tremendous potential in the UC landscape for drugs with better clinical profile especially in terms of safety. Safety concerns associated with JAK inhibitors poses a great opportunity for pharmaceutical companies to work on this front and improve the safety profile of upcoming drugs.
  • Limited treatment options available in case of relapsed or refractory pool, provides lucrative opportunities in the UC therapeutic space.

 

Scope of the Ulcerative Colitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Ulcerative Colitis Companies: AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mesoblast Ltd., InDex Pharmaceuticals, Arena, Protagonist Therapeutics, Palatin Technologies, Inc, Eli Lilly and Company, Pfizer, Janssen Research, Amgen, AbbVie, Landos Biopharma, Ferring Pharma, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma, EA Pharma, Prometheus Biosciences, and others
  • Key Ulcerative Colitis Therapies: isankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Remestemcel-L, Corbitolimod, Etrasimod (APD334), PN-943, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, PRA023 IV, and others
  • Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
  • Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Ulcerative Colitis Unmet Needs, KOL’s views, Analyst’s views, Ulcerative Colitis Market Access and Reimbursement 

 

To know more about Ulcerative Colitis companies working in the treatment market, visit @ Ulcerative Colitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Ulcerative Colitis Market Report Introduction

2. Executive Summary for Ulcerative Colitis

3. SWOT analysis of Ulcerative Colitis

4. Ulcerative Colitis Patient Share (%) Overview at a Glance

5. Ulcerative Colitis Market Overview at a Glance

6. Ulcerative Colitis Disease Background and Overview

7. Ulcerative Colitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Ulcerative Colitis 

9. Ulcerative Colitis Current Treatment and Medical Practices

10. Ulcerative Colitis Unmet Needs

11. Ulcerative Colitis Emerging Therapies

12. Ulcerative Colitis Market Outlook

13. Country-Wise Ulcerative Colitis Market Analysis (2019–2032)

14. Ulcerative Colitis Market Access and Reimbursement of Therapies

15. Ulcerative Colitis Market Drivers

16. Ulcerative Colitis Market Barriers

17.  Ulcerative Colitis Appendix

18. Ulcerative Colitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Insights into Ulcerative Colitis Market 2032: Epidemiological Trends, Pipeline Therapies, and Recent Approvals from FDA, EMA, PDMA Revealed by DelveInsight | Key Players: AbbVie, Boehringer, Eli Lilly

Peripheral Artery Disease Market Expected to Exceed $54 Billion by 2028 | Insights by DelveInsight

“Peripheral Artery Disease Market”

(Albany, USA) DelveInsight’s Peripheral Artery Disease Market Insights report provides the current and forecast market analysis, individual leading peripheral artery disease companies’ market shares, challenges, peripheral artery disease market drivers, barriers, trends, and key market peripheral artery disease companies in the market.

 

Key Takeaways from the Peripheral Artery Disease Market Report

  • As per DelveInsight estimates, North America is anticipated to dominate the global peripheral artery disease market during the forecast period. 
  • Notable peripheral artery disease companies such as Medtronic, Otivio, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Cook, Bayer AG, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX MEDICAL, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Reflow Medical Inc., and several others, are currently operating in the peripheral artery disease market.
  • In August 2023, Following an experimental device exemption (IDE) by the US Food and Drug Administration (FDA), a drug-coated balloon that helps rebuild blood arteries by light activation has been licensed for use in clinical trials in the United States.
  • In July 2023, Endologix LLC, a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced that the first patients underwent Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR system since FDA approval was granted. 
  • In July 2023, the FDA issued a letter to healthcare providers in which it stated that, based on its examination of all available data and analysis, the higher risk of mortality associated with paclitaxel-coated devices for the treatment of PAD is no longer substantiated.
  • In November 2022, the US Food and Drug Administration (FDA) approved Genesis MedTech Group’s Chocolate Touch Drug-coated Balloon (DCB) percutaneous transluminal angioplasty (PTA) Catheter for the treatment of peripheral artery disease (PAD) in the superficial femoral artery and popliteal artery.

 

To read more about the latest highlights related to the peripheral artery disease market, get a snapshot of the key highlights entailed in the Global Peripheral Artery Disease Market Report

 

Peripheral Artery Disease Overview

Peripheral Artery Disease (PAD) is a prevalent circulatory condition that affects the arteries carrying blood away from the heart to the limbs, most commonly the legs. It occurs due to a gradual build-up of plaque within the arteries, leading to a narrowing of the blood vessels and reduced blood flow. As a result, individuals with peripheral artery disease might experience symptoms like cramping, pain, or numbness in their legs, especially during physical activity. If left untreated, peripheral artery disease can have serious consequences, including impaired wound healing and an increased risk of heart attack or stroke. Lifestyle changes, medication, and in severe cases, surgical interventions, can help manage peripheral artery disease, improve blood circulation, and enhance overall quality of life. Regular medical check-ups and early intervention are crucial to effectively manage this condition and minimize its impact.

 

Peripheral Artery Disease Market Insights

North America held the highest share of the peripheral artery disease market in 2021, with 43.53%, and will continue to do so in the coming years. This can be attributed to increasing government initiatives to raise awareness about the effective treatment of peripheral artery diseases, an increasing burden of elderly patients prone to various cardiovascular disorders, an increasing prevalence of obesity, hypertension, and diabetes, and the presence of advanced healthcare facilities in the region, all of which will drive the peripheral artery disease market in North America during the forecast period.

In addition, the increasing number of product launches, approvals, and other regulatory activities among the region’s leading companies would help to boost demand for peripheral artery disease treatment devices and drugs. For instance, Medtronic announced FDA approval for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug-coated balloon (DCB), in May 2022.

 

To know more about why North America is leading the market growth in the peripheral artery disease market, get a snapshot of the Peripheral Artery Disease Market Outlook 

 

Peripheral Artery Disease Market Dynamics

The increasing prevalence of peripheral artery diseases worldwide is one of the important factors impacting the peripheral artery disease market growth. Furthermore, because PAD is largely caused by the development of fatty plaque in the arteries, which is known as atherosclerosis, increasing the prevalence of arteriosclerosis can eventually raise the cases of PAD and boost the market need for peripheral artery disease treatment devices and drugs. In addition, the rising incidence of obesity, diabetes, and high blood pressure will raise the risk of peripheral artery disease, increasing demand for treatment devices and drugs.

However, the high cost of various devices, adverse effects associated with various treatments, and other variables may prove to be difficult factors for the growth of the peripheral artery disease market.

Additionally, during the COVID-19 pandemic, the peripheral artery disease market was significantly damaged. The pandemic’s breakout resulted in the cancellation of outpatient appointments as well as the suspension of non-emergency hospitals and procedures for chronic diseases such as cancer, diabetes, cardiovascular illnesses, stroke, and others. As a result, the number of individuals receiving standard therapy for the aforementioned disease has decreased. Furthermore, numerous elective procedures were postponed in order to treat individuals infected with the coronavirus. Furthermore, constraints on the supply chain, raw materials, and other resources hampered device and drug manufacture, resulting in a shortage of treatment devices and drugs in the peripheral artery disease market.

However, the development of the COVID-19 vaccine kicked off the path of economic recovery. Furthermore, the easing of lockdown restrictions and the return to normalcy in the economic landscape initiated the process of resumption of regular healthcare services such as outpatient visits and surgeries for the treatment of the aforementioned ailments, bringing the demand for products in the peripheral artery disease market back on track.

 

Get a sneak peek at the peripheral artery disease market dynamics @ Peripheral Artery Disease Market Dynamics Analysis

 

Report Metrics

Details

Coverage

Global

Study Period

2020–2028

Peripheral Artery Disease Market CAGR

~7%

Peripheral Artery Disease Market Size by 2027

USD 54.6 Billion

Key Peripheral Artery Disease Companies

Medtronic, Otivio, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Cook, Bayer AG, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX MEDICAL, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Reflow Medical Inc., among others

 

Peripheral Artery Disease Market Assessment

  • Peripheral Artery Disease Market Segmentation
    • Peripheral Artery Disease Market Segmentation By Treatment Type: Devices [Angioplasty Balloon, Angioplasty Stents, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Peripheral Guidewires], and Drugs
    • Peripheral Artery Disease Market Segmentation By End User: Hospitals, Ambulatory Surgical Centers, and Specialty Clinics
    • Peripheral Artery Disease Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

 

Which MedTech key players in the peripheral artery disease market are set to emerge as the trendsetter explore @ Peripheral Artery Disease Companies 

 

Table of Contents 

1. Report Introduction

2. Executive summary

3. Regulatory and Patent Analysis

4. Key Factors Analysis

5. Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Peripheral Artery Disease Market

7. Peripheral Artery Disease Market Layout

8. Global Company Share Analysis – Key 3-5 Companies

9. Peripheral Artery Disease Market Company and Product Profiles

10. Project Approach

11. About DelveInsight

 

About DelveInsight

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peripheral Artery Disease Market Expected to Exceed $54 Billion by 2028 | Insights by DelveInsight

EGFR Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2023” report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the EGFR Non-Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s EGFR Non-Small Cell Lung Cancer pipeline report depicts a robust space with 50+ EGFR Non-Small Cell Lung Cancer companies working to develop 50+ pipeline therapies for EGFR Non-Small Cell Lung Cancer treatment.
  • The leading companies working in the EGFR Non-Small Cell Lung Cancer Market include Alpha Biopharma, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Checkpoint Therapeutics, AbbVie, Akeso Biopharma, Cullinan Oncology, Betta Pharmaceuticals, EpimAb Biotherapeutics, Genor Biopharma, G1 Therapeutics, J Ints Bio, and others.
  • Promising EGFR Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include AZD3759, AZD9291, BBT-207, Icotinib, naquotinib, midazolam, and others.
  • December 2023: Cullinan Oncology Inc. announced a study of Phase 1 & 2 clinical trials for CLN-081. This is a Phase 1/2, open-label, multicenter, first-in-human trial to evaluate the safety and tolerability, PK, PD, and efficacy of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
  • December 2023: Janssen Research & Development LLC announced a study of Phase 1 clinical trials for Amivantamab, Lazertinib, Carboplatin, and Pemetrexed. The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).

 

Request a sample and discover the recent advances in EGFR Non-Small Cell Lung Cancer Treatment Drugs @ EGFR Non-Small Cell Lung Cancer Pipeline Outlook Report

 

In the EGFR Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, EGFR Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

EGFR Non-Small Cell Lung Cancer Overview

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC. Epidermal growth factor receptor is a trans-membrane glycoprotein with an extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase domain that regulates signaling pathways to control cellular proliferation.

 

Find out more about EGFR Non-Small Cell Lung Cancer Therapeutics Assessment @ EGFR Non-Small Cell Lung Cancer Preclinical and Discovery Stage Products

 

EGFR Non-Small Cell Lung Cancer Emerging Drugs Profile

  • AK112: Akeso Biopharma
  • CLN-081: Cullinan Oncology
  • BPI-361175: Betta Pharmaceuticals
  • JANX008: Janux Therapeutics

 

EGFR Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key EGFR Non-Small Cell Lung Cancer companies which are developing the EGFR Non-Small Cell Lung Cancer therapies. The EGFR Non-Small Cell Lung Cancer companies which have their EGFR Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. phase III include, Akeso Biopharma.

 

DelveInsight’s EGFR Non-Small Cell Lung Cancer pipeline report covers around 42+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

EGFR Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging EGFR Non-Small Cell Lung Cancer Pipeline Therapies @ EGFR Non-Small Cell Lung Cancer Clinical Trials Assessment

 

Scope of the EGFR Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • EGFR Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • EGFR Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • EGFR Non-Small Cell Lung Cancer Companies- Alpha Biopharma, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Checkpoint Therapeutics, AbbVie, Akeso Biopharma, Cullinan Oncology, Betta Pharmaceuticals, EpimAb Biotherapeutics, Genor Biopharma, G1 Therapeutics, J Ints Bio, and others.
  • EGFR Non-Small Cell Lung Cancer Pipeline Therapies- AZD3759, AZD9291, BBT-207, Icotinib, naquotinib, midazolam, and others.

 

 

Dive deep into rich insights for new drugs for EGFR Non-Small Cell Lung Cancer Treatment, Visit @ EGFR Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. EGFR Non-Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. EGFR Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. AK112: Akeso Biopharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CLN-081: Cullinan Oncology
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. JANX008: Janux Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. EGFR Non-Small Cell Lung Cancer Key Companies
  21. EGFR Non-Small Cell Lung Cancer Key Products
  22. EGFR Non-Small Cell Lung Cancer- Unmet Needs
  23. EGFR Non-Small Cell Lung Cancer- Market Drivers and Barriers
  24. EGFR Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
  25. EGFR Non-Small Cell Lung Cancer Analyst Views
  26. EGFR Non-Small Cell Lung Cancer Key Companies
  27. Appendix

 

For further information on the EGFR Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to EGFR Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EGFR Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

Recurrent Glioblastoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 50+ Recurrent Glioblastoma companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Recurrent Glioblastoma Pipeline Report

  • DelveInsight’s Recurrent Glioblastoma Pipeline analysis depicts a robust space with 50+ Recurrent Glioblastoma companies working to develop 50+ pipeline treatment therapies.
  • The leading Recurrent Glioblastoma Companies working in the market include Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation LLC, Istari Oncology Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix Inc., NanoPharmaceuticals LLC, Erasca Inc., Oblato Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology Inc., Chimerix, and others.
  • Promising Recurrent Glioblastoma Pipeline Therapies in the various stages of development include ACT001, GX-I7, Bevacizumab, MTX110, Lomustine, TTAC-0001 and pembrolizumab combination, Chemotherapy, and others.
  • December 2023: Jonsson Comprehensive Cancer Center announced a study of phase 2 clinical trials for Osimertinib. This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated glioblastoma.
  • December 2023: Eli Lilly and Company announced a study of phase 2 clinical trials for LY2157299 monohydrate and Lomustine. The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer.
  • On June 2023, Genexine Inc. announced a study of phase 2 clinical trials for GX-17 and Bevacizumab. The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.
  • On May 2023, Biodexa Pharmaceuticals announced a study of phase 1 clinical trials for MTX110 and Lomustine. A study designed to assess the safety of MTX110 alone and in combination with lomustine for patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

 

Request a sample and discover the recent advances in Recurrent Glioblastoma Treatment Drugs @ Recurrent Glioblastoma Pipeline Outlook Report

 

In the Recurrent Glioblastoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Recurrent Glioblastoma Overview

Recurrent Glioblastoma is a possibility that oncologists – and patients – must keep in mind during and after an initial course of treatment. Because it can be difficult to completely remove a tumor during surgery, there is always a possibility that the cancer might come back after a period of remission.

 

Find out more about Recurrent Glioblastoma Therapeutics Assessment @ Recurrent Glioblastoma Preclinical and Discovery Stage Products

 

Recurrent Glioblastoma Emerging Drugs Profile

  • ASC40: Ascletis
  • GX-I7: Genexine
  • Olinvacimab: PharmAbcine
  • VXM01: VAXIMM AG

 

Recurrent Glioblastoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Recurrent Glioblastoma. The Recurrent Glioblastoma companies which have their Recurrent Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Ascletis.

 

DelveInsight’s Recurrent Glioblastoma pipeline report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Recurrent Glioblastoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Learn more about the emerging Recurrent Glioblastoma Pipeline Therapies @ Recurrent Glioblastoma Clinical Trials Assessment

 

Scope of the Recurrent Glioblastoma Pipeline Report

  • Coverage- Global
  • Recurrent Glioblastoma Companies- Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation LLC, Istari Oncology Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix Inc., NanoPharmaceuticals LLC, Erasca Inc., Oblato Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology Inc., Chimerix, and others.
  • Recurrent Glioblastoma Therapies- ACT001, GX-I7, Bevacizumab, MTX110, Lomustine, TTAC-0001 and pembrolizumab combination, Chemotherapy, and others
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for new drugs for Recurrent Glioblastoma Treatment, Visit @ Recurrent Glioblastoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Recurrent Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ASC40: Ascletis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GX-I7: Genexine
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. VXM01: VAXIMM AG
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Recurrent Glioblastoma Key Companies
  21. Recurrent Glioblastoma Key Products
  22. Recurrent Glioblastoma- Unmet Needs
  23. Recurrent Glioblastoma- Market Drivers and Barriers
  24. Recurrent Glioblastoma- Future Perspectives and Conclusion
  25. Recurrent Glioblastoma Analyst Views
  26. Recurrent Glioblastoma Key Companies
  27. Appendix

 

For further information on the Recurrent Glioblastoma Pipeline therapeutics, reach out to Recurrent Glioblastoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent Glioblastoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

Anti-CD20 Antibody Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

DelveInsight’s, “Anti-CD20 Antibody Pipeline Insight 2023” report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Anti-CD20 Antibody Pipeline Report

  • DelveInsight’s Anti-CD20 Antibody pipeline report depicts a robust space with 20+ Anti-CD20 Antibody companies working to develop 20+ pipeline therapies for Anti-CD20 Antibody treatment.
  • The leading companies working in the Anti-CD20 Antibody market include TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
  • Promising Anti-CD20 Antibody Pipeline Therapies in the various stages of development include Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.
  • On July 2023, University of Washington announced a study of Phase 2 Clinical Trials for Obinutuzumab, Rituximab, and Pembrolizumab. This phase II trial studies how well pembrolizumab with rituximab or obinutuzumab work in treating patients with follicular lymphoma or diffuse large B cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory).
  • On July 2023, Cho Pharma Inc. announced a study of Phase 1 & 2 Clinical Trials for CHO-H01. This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin’s lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D).
  • On August 2023, BeiGene announced a study of Phase 3 Clinical Trials for Zanubrutinib, Rituximab, Lenalidomide, and Obinutuzumab. The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

 

Request a sample and discover the recent advances in Anti-CD20 Antibody Treatment Drugs @ Anti-CD20 Antibody Pipeline Report

 

The Anti-CD20 Antibody pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anti-CD20 Antibody drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anti-CD20 Antibody clinical trial landscape.

 

Anti-CD20 Antibody Overview

CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells.

 

Find out more about Anti-CD20 Antibody Treatment Landscape @ Drugs for Anti-CD20 Antibody Treatment

 

Anti-CD20 Antibody Emerging Drugs Profile

  • Ublituximab: TG therapeutics
  • Glofitamab: Roche

 

Anti-CD20 Antibody Pipeline Therapeutics Assessment

The Anti-CD20 Antibody pipeline report proffers an integral view of the Anti-CD20 Antibody emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Anti-CD20 Antibody Pipeline Therapies @ Anti-CD20 Antibody Clinical Trials Assessment

 

Scope of the Anti-CD20 Antibody Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Anti-CD20 Antibody Companies- TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
  • Anti-CD20 Antibody Pipeline Therapies- Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.

 

Dive deep into rich insights for new drugs for Anti-CD20 Antibody Treatment, Visit @ Anti-CD20 Antibody Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Anti-CD20 Antibody: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anti-CD20 Antibody – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Anti-CD20 Antibody Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Ublituximab: TG therapeutics
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Odronextamab: Regeneron Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I)
  16. IGM 2323: IGM Biosciences
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Anti-CD20 Antibody Key Companies
  20. Anti-CD20 Antibody Key Products
  21. Anti-CD20 Antibody- Unmet Needs
  22. Anti-CD20 Antibody- Market Drivers and Barriers
  23. Anti-CD20 Antibody- Future Perspectives and Conclusion
  24. Anti-CD20 Antibody Analyst Views
  25. Anti-CD20 Antibody Key Companies
  26. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anti-CD20 Antibody Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Advanced Endometrial Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

DelveInsight’s, “Advanced Endometrial Cancer Pipeline Insight 2023” report provides comprehensive insights about 25+ Advanced Endometrial Cancer companies and 25+ pipeline drugs in the Advanced Endometrial Cancer pipeline landscape. It covers the Advanced Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Endometrial Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Endometrial Cancer Pipeline Report

  • DelveInsight’s Advanced Endometrial Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Advanced Endometrial Cancer treatment.
  • The leading companies working in the Advanced Endometrial Cancer market include Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
  • Promising Advanced Endometrial Cancer pipeline therapies in the various stages of development include Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
  • On January 2023, 3D Medicines (Sichuan) Co. Ltd announced a study of Phase 2 clinical trials for Envafolimab. This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer. The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.
  • On June 2023, Eisai Inc. announced a study of Phase 2 clinical trials for Lenvatinib. To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy.
  • On July 2023, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. announced a study of Phase 2 clinical trials for TQB2450 injection and Docetaxel injection. This study plans to enroll 69 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The experimental set is divided into lead-in trial and formal trial. The lead-in trial includes 9 subjects to observe the safety of the combination and determine the dosage of anlotinib dihydrochloride capsules before the formal phase.
  • On August 2023, Tesaro Inc. announced a study of Phase 3 clinical trials for Dostarlimab, Carboplatin, Paclitaxel, and Niraparib. This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.

 

Request a sample and discover the recent advances in Advanced Endometrial Cancer Treatment Drugs @ Advanced Endometrial Cancer Infection Pipeline Report

 

The Advanced Endometrial Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Endometrial Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Endometrial Cancer clinical trial landscape.

 

Advanced Endometrial Cancer Overview

Metastatic or advanced uterine (endometrial) cancer is a type of cancer that originated in the lining of the uterus (endometrium) and has spread to distant areas of the body. In general, uterine cancer can metastasize to the rectum or bladder.

 

Find out more about Advanced Endometrial Cancer Treatment Landscape @ Drugs for Advanced Endometrial Cancer Treatment

 

Advanced Endometrial Cancer Emerging Drugs Profile

  • Retifanlimab: Incyte Corporation
  • Trastuzumab duocarmazine (SYD985): Byondis

 

Advanced Endometrial Cancer Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Advanced Endometrial Cancer. The Advanced Endometrial Cancer companies which have their Advanced Endometrial Cancer drug candidates in the most advanced stage, i.e. phase II include, Incyte Corporation.

 

Learn more about the emerging Advanced Endometrial Cancer Pipeline Therapies @ Advanced Endometrial Cancer Clinical Trials Assessment

 

Scope of the Advanced Endometrial Cancer Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Advanced Endometrial Cancer- Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
  • Advanced Endometrial Cancer pipeline therapies- Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.

 

Dive deep into rich insights for new drugs for Advanced Endometrial Cancer treatment, Visit @ Advanced Endometrial Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Endometrial Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Endometrial Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Selinexor: Karyopharm Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Retifanlimab: Incyte Corporation
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Alsevalimab: Five Prime Therapeutics
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Advanced Endometrial Cancer Key Companies
  18. Advanced Endometrial Cancer Key Products
  19. Advanced Endometrial Cancer- Unmet Needs
  20. Advanced Endometrial Cancer- Market Drivers and Barriers
  21. Advanced Endometrial Cancer- Future Perspectives and Conclusion
  22. Advanced Endometrial Cancer Analyst Views
  23. Advanced Endometrial Cancer Key Companies
  24. Appendix

 

For further information on the Advanced Endometrial Cancer pipeline therapeutics, reach out to Advanced Endometrial Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Endometrial Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Advanced Merkel Cell Carcinoma Pipeline, FDA Approval, Clinical Trials Development and Companies 2023 (Updated)

DelveInsight’s, “Advanced Merkel cell carcinoma Pipeline Insight 2023″ report provides comprehensive insights about 20+ Advanced Merkel Cell Carcinoma Companies and 20+ pipeline drugs in the Advanced Merkel cell carcinoma pipeline landscape. It covers the Advanced Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Merkel Cell Carcinoma Pipeline Report

  • DelveInsight’s Advanced Merkel Cell Carcinoma pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Advanced Merkel Cell Carcinoma treatment.
  • The leading companies working in the Advanced Merkel Cell Carcinoma market include Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
  • Promising Advanced Merkel Cell Carcinoma Pipeline Therapies in the various stages of development include Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.
  • December 2023: Regeneron Pharmaceuticals announced a study of Phase 2 clinical trials for vidutolimod and cemiplimab. The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have an end of treatment visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
  • December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab (MK-3475). This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.
  • On August 2023, H. Lee Moffitt Cancer Center and Research Institute announced a study of Phase 1 Clinical Trials for Cemiplimab-Rwlc. The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
  • On July 2023, 4SC AG announced a study of Phase 2 Clinical Trials for Domatinostat in Combination with Avelumab. This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody.
  • On June 2023, Memorial Sloan Kettering Cancer Center announced a study of Phase 2 Clinical Trials for Avelumab. This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out if CART works well when combined with avelumab.
  • On February 2023, Merck Sharp & Dohme LLC announced a study of Phase 3 Clinical Trials for Pembrolizumab (MK-3475). This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.

 

Request a sample and discover the recent advances in Advanced Merkel Cell Carcinoma Treatment Drugs @ Advanced Merkel Cell Carcinoma Infection Pipeline Report

 

The Advanced Merkel Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Merkel Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Merkel Cell Carcinoma clinical trial landscape.

 

Advanced Merkel Cell Carcinoma Overview

Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease.

 

Find out more about Advanced Merkel Cell Carcinoma Treatment Drugs @ Drugs for Advanced Merkel Cell Carcinoma Treatment

 

Advanced Merkel Cell Carcinoma Emerging Drugs Profile

  • Tidutamab: Xencor, Inc.
  • Cabozantinib: Exelixis

 

Advanced Merkel Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Advanced Merkel cell carcinoma. The Advanced Merkel Cell Carcinoma companies which have their Advanced Merkel cell carcinoma drug candidates in the most advanced stage, i.e. phase II include, Exelixis.

 

Learn more about the emerging Advanced Merkel Cell Carcinoma Pipeline Therapies @ Advanced Merkel Cell Carcinoma Clinical Trials Assessment

 

Scope of the Advanced Merkel Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Advanced Merkel Cell Carcinoma Companies- Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
  • Advanced Merkel Cell Carcinoma Pipeline Therapies- Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.

 

Dive deep into rich insights for new drugs for Advanced Merkel Cell Carcinoma treatment, Visit @ Advanced Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Merkel cell carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Merkel cell carcinoma – DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase II)
  8. Cabozantinib: Exelixis
  9. Drug profiles in the detailed report…..
  10. Early Stage Products (Phase I)
  11. IFx-Hu2.0: Morphogenesis
  12. Drug profiles in the detailed report…..
  13. Inactive Products
  14. Advanced Merkel cell carcinoma Key Companies
  15. Advanced Merkel cell carcinoma Key Products
  16. Advanced Merkel cell carcinoma- Unmet Needs
  17. Advanced Merkel cell carcinoma- Market Drivers and Barriers
  18. Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
  19. Advanced Merkel cell carcinoma Analyst Views
  20. Advanced Merkel cell carcinoma Key Companies
  21. Appendix

 

For further information on the Advanced Merkel Cell Carcinoma pipeline therapeutics, reach out to Advanced Merkel Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Merkel Cell Carcinoma Pipeline, FDA Approval, Clinical Trials Development and Companies 2023 (Updated)